Dr. Gautam Borthakur, M.D.
Claim this profileMD Anderson Cancer Center
Area of expertise
Acute Myelogenous Leukemia
Gautam Borthakur, M.D. has run 13 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
Acute Myeloid Leukemia
Gautam Borthakur, M.D. has run 13 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
The University Of Texas M.D. Anderson Cancer Center
Clinical Trials Gautam Borthakur, M.D. is currently running
Iadademstat + Gilteritinib
for Acute Myeloid Leukemia
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Recruiting
1 award
Phase 1
BTX-A51
for Leukemia
This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done in three parts. Part 1a (Monotherapy Dose Escalation) of this study is designed to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered BTX-A51 in up to 35 participants who are evaluable for toxicity. Once the MTD is determined, it is planned that an additional 15 participants will be enrolled in Part 1b (Monotherapy Cohort Expansion) of this study for additional experience with safety and efficacy, and to determine the recommended Phase 2 dose (RP2D) which may or may not be different from the MTD. After determination of MTD and RP2D from Part 1a, Part 1c (Azacitidine Combination Dose Escalation) will enroll up to 30 participants. Continued treatment will be available under this study protocol for up to eight 28-day cycles (Continued Treatment Phase) if the Investigator judges the benefit outweighs the risk. Once BTX-A51 treatment has completed, participants will be contacted by telephone every 3 months for up to 2 years after their last treatment for survival status and anticancer therapy (Overall Survival Follow-up).
Recruiting
1 award
Phase 1
7 criteria
More about Gautam Borthakur, M.D.
Clinical Trial Related
5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Gautam Borthakur, M.D. has experience with
- Azacitidine
- Venetoclax
- Decitabine
- Nadunolimab
- Cytarabine
- Filgrastim-sndz
Breakdown of trials Gautam Borthakur, M.D. has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myelodysplastic syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gautam Borthakur, M.D. specialize in?
Gautam Borthakur, M.D. focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved FLT3 positive patients, or patients who are N.
Is Gautam Borthakur, M.D. currently recruiting for clinical trials?
Yes, Gautam Borthakur, M.D. is currently recruiting for 5 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Gautam Borthakur, M.D. has studied deeply?
Yes, Gautam Borthakur, M.D. has studied treatments such as Azacitidine, Venetoclax, Decitabine.
What is the best way to schedule an appointment with Gautam Borthakur, M.D.?
Apply for one of the trials that Gautam Borthakur, M.D. is conducting.
What is the office address of Gautam Borthakur, M.D.?
The office of Gautam Borthakur, M.D. is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.